Basic Information
| LncRNA/CircRNA Name | CDKN2B-AS1 |
| Synonyms | NA |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RIP, Luciferase reporter assay |
| Sample | hepatocellular carcinoma tissues, cell lines (HepG2, Huh7, SMMC-7721, LO2) |
| Expression Pattern | up-regulated |
| Function Description | Here, we identified a novel oncogenic lncRNA CDKN2B-AS1, which was highly expressed in HCC and positively associated with large tumor size, microvascular invasion, high tumor grade, advanced tumor stage and reduced survival of HCC patients. CDKN2B-AS1 knockdown inhibited cell proliferation, migration and invasion, CDKN2B-AS1 promoted nucleosome assembly protein 1 like 1 (NAP1L1) expression by sponging let-7c-5p. CDKN2B-AS1 knockdown inhibitedcell proliferation, migration and invasion, and induced G1 arrest and apoptosis of HCC cellsin vitro. |
| Pubmed ID | 30165194 |
| Year | 2018 |
| Title | LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. |
External Links
| Links for CDKN2B-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |